Company Receives additional 180-day grace period, until June 28, 2021 , to satisfy the $1.00 bid price requirement to maintain Nasdaq listing Trading on Nasdaq Capital Market is expected to begin on December 30, 2020 LAKE FOREST, Ill. , Dec. 29, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc.

Expected to Reduce Costs by $45 Million Annually LAKE FOREST, Ill. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced a comprehensive restructuring plan designed to further reduce its cost base and right size its organization.

LAKE FOREST, Ill. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings , Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that President, chief executive officer and director, Todd Smith will present at and participate in investor meetings at

Reported Net Product Sales of $34.3 Million   Non-GAAP Net Product Sales of $33.7 Million ; Increased 21.4% over Pro-Forma Second Quarter 2020 Non-GAAP Net Product Sales Consistent with Pro-Forma Prior Year Quarter Despite COVID-19 Related Sales Disruptions and Effects of Sales Force Integration

LAKE FOREST, Ill. , Oct. 23, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its third quarter 2020 financial results will be released on Friday, November 6, 2020 .

LAKE FOREST, Ill. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that the company will present at and participate in investor meetings at the Cantor Virtual Global Healthcare Conference

--Completed all merger and integration activities in Q2-- --Repaid $10 million of Senior Secured Notes ahead of schedule-- --Zyla products partially contributed to Q2 net product sales of $20.2 million -- --Combined second quarter 2020 net product sales of $27.7 million , on a pro forma basis,

LAKE FOREST, Ill. , July 20, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2020 financial results will be released on Friday, August 7, 2020 .

Trading under ASRT on Nasdaq Global Select Market Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million¹ Upwards of $40 million in Expected Cost Synergies LAKE FOREST, Ill. , May 20, 2020 /PRNewswire/ -- Assertio Holdings, Inc., the successor issuer to Assertio

-- Completed Strategic Asset Sales of NUCYNTA ® Franchise and Gralise ® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt -- -- Merger with Zyla Life Sciences On Track and Expected to Close Shortly After the Company’s 2020 Annual Meeting